PreciseDx today announced its attendance and participation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
The poster presentation features findings from PreciseDx’s collaboration with the Laboratory of Pathology, Dordrecht Albert Schweitzer Hospital in the Netherlands. NEW YORK, May 28, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for morphology-driven disease analysis, today announced its attendance and participation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. PreciseDx Co-Founder and Chief Medical Officer, Michael J. Donovan, PhD, MD, will present the findings from the company’s ongoing collaboration with the Laboratory of Pathology, Dordrecht Albert Schweitzer Hospital in the Netherlands (NTH). The poster presentation, “AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low Risk Cohort from the Netherlands with a Median 6-Year Follow-Up,” will be presented on June 1st. Traditional invasive breast cancer (IBC) grading remains limited due to diagnostic subjectivity. PreciseDx® has developed PreciseBreast™, a test validated to predict the risk of recurrence in early-stage breast cancer patients. The test leverages Artificial Intelligence (AI), morphological features, and clinical data to provide an objective risk score. This study evaluates the performance of PreciseBreast™ as compared to MammaPrint in a cohort of patients with outcome data. In this study, a MammaPrint cohort with a median 6-year follow-up was examined. Hematoxylin and Eosin (H&E) stained images, digitized at Philips in Eindhoven, NTH, were coupled with clinical data from pathology and Netherlands cancer registries. This comprehensive dataset encompassed demographics, pathology results, MammaPrint risk classification, treatment details, and recurrence events. The validated PreciseBreast™ (PDxBr) model was then assessed on this MammaPrint cohort using key performance indicators such as AUC (area under the curve)/concordance index, NPV (negative predictive value), PPV (positive predictive value), hazards ratio (HR), sensitivity, and specificity to evaluate its efficacy. “We initiated this collaboration with the Dordrecht Albert Schweitzer Hospital in 2022 and have since made considerable progress in further validating the efficacy of our PreciseBreast™ test and overall phenotyping platform,” said Dr. Donovan. “We look forward to sharing the results of our ongoing study with our colleagues and peers at the 2024 ASCO Annual Meeting.” The poster presentation details can be found here:
The American Society of Clinical Oncology Annual Meeting, founded in 1964, is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. About PreciseDx About PreciseBreast™ About ASCO For media inquiries, please contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/precisedx-announces-poster-presentation-at-the-2024-american-society-of-clinical-oncology-annual-meeting-302155480.html SOURCE PreciseDx |